Copenhagen and Oslo, 14th July, 2011, 2011-07-14 08:20 CEST (GLOBE NEWSWIRE) -- Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced today according to the Danish Securities Act section 29, cf. executive order no. 795 of 20th August, 2009 on major shareholders, that Trans Nova Investments Ltd. on July 13th, 2011 has reduced the number of shares in Affitech A/S from 260,187,010 shares of each DKK 0.50/number of voting rights (equal to 53.34% of Affitech A/S’ total share capital /number of voting rights) to 195,140,258 shares of each DKK 0.50 equal to 40% af Affitech A/S’ total share capital/number of voting rights.
The company has one share class.
About Affitech
Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech’s premier discovery engine for the isolation of lead antibodies to cell surface molecules. Affitech co-develops its two lead antibody drug candidates AT001/r84 and AT008/CCR4 with Russian partner IBC Generium. Further information is available at www.affitech.com.
Disclaimer
This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of the financial condition and operations of Affitech A/S. There are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forecasts. These factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to transact viable and profitable commercial deals, the risk of non-approval of patents not yet granted, and difficulties of obtaining relevant governmental approvals for new products.
No expressed or implied representations or warranties are given concerning Affitech A/S or the accuracy or completeness of the information provided herein, and no claims shall be made by the recipient of this news release by virtue of the information contained herein.
Contact:
Randi Krogsgaard, Director IR & Corporate Communications
Tel. +45 2320 1001, e-mail: ir@affitech.com
